// App-Quantinova.ai

271 : Second-line tyrosine kinase inhibitors (TKIs) versus immunotherapy (IO) for advanced hepatocellular carcinoma (HCC): Real-world efficacy and safety analysis in patients with varying liver dysfunction.

Researchers

Presenter

  • Jeffrey Xia

Principal Investigators

  • Jonathan Gelfond

  • Sukeshi Patel Arora

Medical Centers

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

  • Solid malignancies

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Cabozantinib

  • Regorafenib

  • Nivolumab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved